Pharmaron Holdings Ltd. has acquired Bridge Laboratories China, a provider of GLP-compliant toxicology services to pharma and biopharmaceutical companies. With this acquisition, Pharmaron becomes an integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings. Bridge Laboratories China has 84,000 sq. ft. of facilities, including animal vivariums that are both AAALAC multi-species accredited and U.S. GLP-compliant. Terms of the acquisition were not disclosed.

“Pharmaron has built an exceptional team of scientists specialized in the areas of discovery and process chemistry, biology, DMPK, pharmacology and GMP manufacturing. The acquisition of Bridge Laboratories China enhances our drug R&D service capabilities by adding world-class expertise in western standard GLP-compliant toxicology and safety pharmacology to our diverse service portfolio,” said Pharmaron chairman and chief executive officer Dr. Boliang Lou. “Pharmaron is now the first CRO in China to provide fully integrated drug discovery and development services, from discovery chemistry to IND filings.”

“As a premier provider of drug discovery services, Pharmaron was an ideal partner given the company’s diverse customer base of leading biotech and pharmaceutical companies,” said Bridge Laboratories chief executive officer Tom Oakley. “The addition of Bridge’s U.S. GLP-compliant toxicology expertise will make Pharmaron the first company in China to provide truly integrated drug development services from discovery to IND.”